Resumen
El levetiracetam es un antiepiléptico derivado de las pirrolidonas, altera los niveles de calcio intraneuronal reduciendo su liberación de los depósitos intracelulares, inhibe parcialmente los canales de calcio tipo N, y revierte parcialmente la reducción en las corrientes de GABA y glicina inducidas por el Zinc y las ?-carbolinas, posee un perfil farmacocinético y de seguridad favorable que lo han convertido en un medicamento de utilidad en el manejo adyuvante de crisis parciales no controladas. Se presentan 4 casos de pacientes manejados con levetiracetam innovador, que presentaron eventos adversos intolerables y fallo terapéutico al cambiar a levetiracetam genérico, se concluye que se necesitan estudios locales adicionales para corroborar que cambio hacia el levetiracetam genérico pueden afectar la adherencia al tratamiento por parte de los pacientes y generar situaciones potencialmente fatales como estado epiléptico.
Citas
AMINOFF M. Nervous System Disorders. In: McPhee SJ, Ed. Current Medical Diagnosis & Treatment. 49 Ed. New York: Mc GrawHill; 2010: 878-884.
VELEZ A, ESLAVA-COBOS J. Epilepsy in Colombia: epidemiologic profile and classification of epileptic seizures and syndromes. Epilepsia. 2006; 47: 193-201
SHORVON SD, RIJCKEVORSEL K. A new antiepileptic drug. J Neurol Neurosurg Psychiatry. 2002; 72: 426-428.
LYNCH BA, LAMBENG N, NOCKA K, ET AL. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug Levetiracetam. PNAS. 2004; 101: 9861-9866.
PATSALOS PN. Pharmacokinetic profile of Levetiracetam: toward ideal characteristics. Pharmacology & Therapeutics 2000; 85: 77-85.
FRENCH J, EDRICH P, CRAMER JA. A systematic review of the safety profile of Levetiracetam: a new antiepileptic drug. Epilepsy Research 2001; 47: 77-90.
NICOLAS JM, COLLART P, GERIN B, ET AL. Invitro evaluation of potential drug interactions with Levetiracetam, A new antiepileptic agent. Drug Metabolism and Disposition. 1999; 27: 250-254.
KWAN P, LIM SH, CHINVARUN Y, ET AL. Efficacy and safety of Levetiracetam as adjunctive therapy in adult patients with uncontrolled partial epilepsy. Epilepsy and Behavior. 2010; 18: 100-105.
ARMSTRONG TS, CHOI S, WALKER J, GILBERT MR. Seizure risk in brain tumor patients with conversion to generic Levetiracetam. Journal of Neuro Oncology. 2010; 98: 137-41.
PRIVITERA MD. Generic Antiepileptic Drugs: Current Controversies and Future Directions. Epilepsy Currents. 2008; 8: 113-117.
Antiepileptic drugs: the drawbacks of generic substitution [editorial]. Lancet Neurology. 2010; 9: 227.
GOMEZ J, KANNER A, HERRANZ JL, MOLINS A, GIL-NAGEL A. Risks and Benefits of Generic Antiepileptic Drugs. The Neurologist. 2008; 14 (Suppl) s66-s72.
GAUTHIER-LEWIS M, RILEY T. Generic substitution of antiepileptic medications in patients with epilepsy: Is this a potential problem? Am J Health-Syst Pharm. 2009; 66: 1903-1904.
BERG MJ, GROSS RA, TOMASZEWSKI KJ, ZINGARO WM, HASKINS LS. Generic substitution in the treatment of epilepsy. Neurology. 2008; 71: 525-530.
LABINER DM, PARADIS PE, MANJUNATH R, DUH MS, ET AL. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology. 2010; 74: 1566-1574.
DUH MS, CAHIL KE, PARADIS PE, CREMIEUX PY, GREENBERG PE. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence. Expert Opinion Pharmacotherapy. 2009; 10: 2317-2328.
HELMERS SL, PARADIS PE, MANJUNATH R, DUH MS, LAFEUILLE MH, LATREMOUILLE-VIAU D, LEFEBVRE P, LABINER DM. Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy & Behavior. 2010; 18: 437-444.
CHALUVADI S, CHIANG S, TRAN L, GOLDSMITH CE, FRIEDMAN DE. Clinical experience with generic levetiracetam in people with epilepsy. Epilepsia. 2011 DOI: 10.1111/j.1528-1167.2011.03025.x
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.